Follistatin 315 vs Tesofensine
Side-by-side comparison of key properties, dosing, and research.
Anabolic & IGF
Follistatin 315Fat Loss & Metabolic
Tesofensine- Summary
- Follistatin 315 is a splice variant isoform of follistatin produced by alternative mRNA processing. Unlike Follistatin 344 which is tethered to cell surfaces via heparan sulfate proteoglycans, FST-315 circulates freely in the bloodstream and has broader systemic distribution. It is the predominant circulating form and exerts systemic myostatin inhibition as well as FSH suppression, making it relevant to both muscle growth and reproductive endocrinology.
- Tesofensine is a triple monoamine reuptake inhibitor (TMRI) that blocks reuptake of serotonin, dopamine, and norepinephrine. Originally developed for Alzheimer's and Parkinson's disease, it was repurposed as a potent weight loss agent after clinical trials demonstrated substantial fat loss via appetite suppression and increased energy expenditure.
- Half-Life
- ~3–5 hours (longer systemic circulation vs FST-344)
- 8-10 days (exceptionally long; accumulates over weeks)
- Admin Route
- SubQ, IM
- Oral
- Research
- —
- —
- Typical Dose
- No established human dosing protocol
- 0.25-0.5 mg per day
- Frequency
- Research use only
- Once daily
- Key Benefits
- Systemic myostatin inhibition for whole-body muscle growth
- Freely circulating — broader tissue distribution than FST-344
- Strong FSH-suppressive activity useful in certain hormonal protocols
- Potential for greater anabolic effect across multiple muscle groups simultaneously
- May be more relevant to reproductive endocrinology applications
- Studied in gene therapy approaches for muscular dystrophy
- Potent appetite suppression via triple monoamine reuptake inhibition
- Significant weight loss (8-12% body weight in phase II trials at 0.5 mg)
- Increases basal metabolic rate and energy expenditure
- Reduces fat mass preferentially over lean mass
- Potential cognitive benefit via dopaminergic and noradrenergic enhancement
- Longer half-life than sibutramine allows once-daily dosing
- Side Effects
- Systemic FSH suppression — significant concern for fertility
- Greater potential for off-target effects vs FST-344 due to systemic distribution
- Limited human safety data
- Potential cardiac hypertrophy with prolonged high-dose exposure
- Elevated heart rate and blood pressure (sympathomimetic)
- Dry mouth
- Insomnia and sleep disturbances
- Nausea
- +4 more
- Stacks With
- —
- —